Welcome to our dedicated page for ONTX news (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on ONTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONTX's position in the market.
Onconova Therapeutics (NASDAQ: ONTX) reported Q2 2020 financial results and provided a business update on August 12, 2020. The company confirmed that its INSPIRE Phase 3 trial met the required survival events for data analysis, with topline results expected by Q3 2020. If successful, they plan to submit a New Drug Application for rigosertib, which aims to improve survival in higher-risk myelodysplastic syndromes (MDS). The company held $27.2 million in cash as of June 30, with a net loss of $7.4 million for the quarter.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) plans to release its second quarter financial results on August 12, 2020. The biopharmaceutical company focuses on novel cancer treatments, specifically targeting myelodysplastic syndromes (MDS). Following the results, management will host a conference call at 4:30 p.m. ET to discuss the outcomes and updates on pipeline programs. The lead compound, rigosertib, is currently under advanced clinical trials, with the INSPIRE trial assessing its efficacy in higher-risk MDS patients. The company aims to address significant unmet medical needs in cancer care.
Onconova Therapeutics (NASDAQ: ONTX) announced it regained compliance with Nasdaq's minimum bid price requirement on August 3, 2020, following ten consecutive business days of its common stock closing at or above $1.00 per share. As a Phase 3 biopharmaceutical company, Onconova focuses on developing treatments for myelodysplastic syndromes (MDS), primarily through its lead compound, rigosertib. Ongoing clinical trials aim to address unmet medical needs in higher-risk MDS patients, with both intravenous and oral formulations of rigosertib being explored.
On July 29, 2020, Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced that the necessary number of survival events for its pivotal Phase 3 INSPIRE trial has been reached. Topline data from the trial, which assesses IV rigosertib for higher-risk myelodysplastic syndromes (HR-MDS), is expected to be released by the end of Q3 2020. The trial, guided by the FDA and EMA, is designed to evaluate the efficacy and safety of rigosertib in patients who have failed prior treatment. This pivotal moment brings the company closer to addressing significant unmet medical needs in cancer treatment.
Onconova Therapeutics (NASDAQ: ONTX) has published new in vitro data supporting its lead candidate, rigosertib, as an effective modulator of RAS signaling. The findings indicate that clinical-grade rigosertib differs from non-clinical grade versions, which contain impurities affecting cellular function. These results bolster the rationale for rigosertib's investigation in treating RAS-driven diseases, addressing a significant unmet need in cancer treatment. Onconova plans to present its ongoing research efforts at the upcoming RAS-Targeted Drug Development Summit in September 2020.
Onconova Therapeutics (NASDAQ: ONTX), a Phase 3 biopharmaceutical company specializing in cancer treatments, participated in the Noble Capital Markets webinar on June 16. Key figures from the company, including CEO Steven M. Fruchtman, discussed recent developments and milestones. Onconova focuses on myelodysplastic syndromes (MDS) and is advancing trials for its lead compound, rigosertib. The INSPIRE trial assesses rigosertib’s efficacy in higher-risk MDS patients, aiming for improved survival rates. The trial's details and further information are available on clinicaltrials.gov.
Onconova Therapeutics (NASDAQ: ONTX) presented updated baseline genomic data from HMA-failure patients for the INSPIRE trial at the 25th Annual EHA Congress. The analysis identified over 45 driver mutations in higher-risk MDS patients, with 55 different mutations found at baseline, and a median of three mutations per patient. RAS pathway mutations were more common in patients who progressed on HMA therapy. The ongoing INSPIRE trial is assessing the efficacy and safety of IV rigosertib in higher-risk MDS patients who failed prior treatments. The trial's primary endpoint is overall survival.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) will release its first quarter financial results on May 14, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and updates on its pipeline, particularly focusing on myelodysplastic syndromes (MDS). Interested parties can join via phone or webcast. Onconova is in Phase 3 of developing its lead compound, rigosertib, aimed at addressing unmet medical needs in MDS. The company acknowledges uncertainties and risks related to its clinical trials and going concern status.